Undetectable equals untransmittable. Many people not intimately involved in the HIV community have never heard about the concept of U=U. Simply stated, the Prevention Access Campaign’s Undetectable = Untransmittable message underscores that a person living with HIV who is on antiretroviral therapy (ART) and has a sustained undetectable viral load for at least six months, has a negligible risk of sexual transmission of HIV.
In October 2017, Napo Pharmaceuticals was proud to join over 400 organizations from 59 countries in support of the U=U Consensus Statement. This scientific consensus statement has been endorsed by leading HIV experts, and researchers from around the world and Napo supports this message to raise global awareness about the effectiveness of HIV treatment and to destigmatize the disease.
“Napo has been and continues to be an advocate for the HIV community and their healthcare providers through our endorsement of the U=U Consensus Statement, our sponsorship of the My HIV Thank You platform, and our educational awareness programs. We firmly believe that living with HIV requires access to the most up-to-date research and experts,” said Lisa Conte, CEO, Napo Pharmaceuticals. “In addition, we have launched educational awareness programs targeting chronic diarrhea, as it continues to be a significant, neglected symptom in HIV/AIDS patients. Relevant to the U=U movement, diarrhea can lead patients to interrupt or discontinue their ART.”
“U=U is a life-changing message for people living with HIV, but not enough people know about it yet,” said Bruce Richman, who was diagnosed in 2003 and is the Executive Director of Prevention Access Campaign. “We’re thrilled that Napo is joining the U=U campaign to empower people with HIV with the knowledge that changes lives, dismantles stigma, and gets us closer to ending the epidemic.”